Please assess the completion status of the following clinical trial:

Trial Title: Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of facial capillary malformation (port-wine stain, PWS) made by a dermatologist~* age: 12-17 years of age~* weight \> 45 kg~* lesions with a surface area \< 100 cm2~* signed consent and assent for study participation~Exclusion Criteria:~* skin breakdown overlying the malformation due to other dermatological conditions (e.g. eczema, psoriasis)~* current or treatment with laser the past 3 months~* other topical treatments used within the past 4 weeks (e.g. rapamycin, corticosteroids, calcineurin inhibitors, etc)~* known chronic renal or hepatic disorders~* known cardiovascular disorders~* other systemic medications that potentially interact with Brimonidine (opiates, chlorpromazine, methyphenidate, reserpine, etc)~* mixed capillary/ venous or lymphatic malformations~* known allergy to one of the constituents of Onreltea~* pregnancy, or sexually active subjects of child-bearing potential (CBP), unwilling to use contraception during the study (such as barrier method, or oral contraceptives).

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Onreltea ( Brimonidine) (Type: EXPERIMENTAL): All the patients enrolled in the study will apply Onreltea ( Brimonidine 0.33%) gel on the affected skin area for 12 weeks (from Day 0 to Week 12 visit).

Based on this trial design, predict the completion outcome and termination type (if applicable).